Previous Close | 73.90 |
Open | 74.05 |
Bid | 72.60 x 100 |
Ask | 73.08 x 100 |
Day's Range | 72.62 - 74.70 |
52 Week Range | 49.24 - 94.57 |
Volume | |
Avg. Volume | 181,373 |
Market Cap | 1.308B |
Beta (5Y Monthly) | 0.92 |
PE Ratio (TTM) | 24.04 |
EPS (TTM) | N/A |
Earnings Date | N/A |
Forward Dividend & Yield | N/A (N/A) |
Ex-Dividend Date | Jul 02, 2010 |
1y Target Est | N/A |
JUPITER, Fla., April 23, 2024--Ligand Pharmaceuticals Incorporated (Nasdaq: LGND) today announced that it will report first quarter 2024 financial results after the close of the U.S. financial markets on Tuesday, May 7, 2024, and will hold a conference call at 4:30 p.m. Eastern Time that same day to discuss financial results and provide a general business update.
LONDON, April 08, 2024--Ligand Pharmaceuticals Incorporated (Nasdaq: LGND) today announced that its partners at the University of Minnesota (UMN) and CURx Pharmaceuticals, Inc. presented new data on Captisol-enabled™ Topiramate Injection (IV topiramate), a potential replacement therapy for the treatment of certain emergent neurological conditions, including epilepsy, when oral administration is not feasible.
JUPITER, Fla. & DURHAM, N.C., April 03, 2024--Ligand Pharmaceuticals (Nasdaq: LGND) today announced the launch of Pelthos Therapeutics (Pelthos), a biopharmaceutical company, and the appointment of seasoned industry executive Scott Plesha to the role of Chief Executive Officer.